GlassScriptPhysician profile
Arunima Sharma
NPI 1932562808
$592.98
in general payments reported to CMS, 2019-2025
10 companies · $44.81 in 2025
The $44.81 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.83 · 2020: $71.16 · 2021: $155 · 2022: $217 · 2023: $46.64 · 2024: $22.15 · 2025: $44.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $113.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $175.22 | 2022-2024 | Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.35 | 2019-2022 | |
| Insmed, INC. | $58.88 | 2021-2025 | Arikayce |
| Grifols USA, LLC | $52.58 | 2023-2025 | Prolastin-C Liquid |
| Pfizer INC. | $48.86 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $39.99 | 2020-2022 | |
| Glaxosmithkline, LLC. | $25.35 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $22.31 | 2021 | |
| Gilead Sciences, INC. | $14.86 | 2021 | |
| Genentech USA, INC. | $12.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arunima Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.